• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Arava (leflunomide) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

November 2012

Summary View

ADVERSE REACTIONS

Post-Marketing Experience
  • cutaneous lupus erythematosus, pustular psoriasis or worsening psoriasis

 

July 2011

Summary View

WARNINGS

  • Peripheral neuropathy section added

PRECAUTIONS

Respiratory
  • .....risk of interstitial lung disease

 

September 2010

Summary View

BOXED WARNING

  • If ALT elevation > 3 fold ULN occurs, interrupt Arava therapy while investigating the probable cause of the ALT elevation by close observation and additional tests. If likely leflunomide-induced, start cholestyramine washout and monitor liver tests weekly until normalized. If leflunomide-induced liver injury is unlikely because some other probable cause has been found, resumption of Arava therapy may be considered.

WARNINGS

Hepatotoxicity
  • If ALT elevation > 3 fold ULN occurs, interrupt Arava therapy while investigating the probable cause of the ALT elevation by close observation and additional tests. If likely leflunomide-induced, start cholestyramine washout and monitor liver tests weekly until normalized. If leflunomide-induced liver injury is unlikely because some other probable cause has been found, resumption of Arava therapy may be considered.